Correction: γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers

Nuša Trošt; Samuel Peña-Llopis; Sajjan Koirala; Jurij Stojan; Patrick Ryan Potts; Klementina Fon Tacer; Elisabeth D. Martinez

doi:10.18632/oncotarget.26649

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers

PDF | How to cite

Oncotarget. 2019; 10:916-916. https://doi.org/10.18632/oncotarget.26649

Metrics: PDF 1378 views | ?

Nuša Trošt^1,2, Samuel Peña-Llopis², Sajjan Koirala³, Jurij Stojan¹, Patrick Ryan Potts³, Klementina Fon Tacer³ and Elisabeth D. Martinez^2,4

¹ Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
² Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
³ Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
⁴ Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Published: January 25, 2019

This article has been corrected: The correct Keywords are given below:

Keywords: LCTL; gamma Klotho; FGF; breast cancer; cancer therapy; ROS; oxidative stress; oncogene

Original article: Oncotarget. 2016; 7:2611-2628. DOI: https://doi.org/10.18632/oncotarget.6006.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26649

Publication Alerts

Corrections:

Correction: γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers